Change in secondary lipid measures from baseline to weeks 21 and 34, showing means ± standard deviation.
| Absolute change from baseline | ||||
|---|---|---|---|---|
| Bendrofluazide (n) | Doxazosin (n) | Adjusted treatment difference (95% CI) | P-value | |
| LDL-C (mmol/l) | ||||
| Baseline | 3.97±0.861 (81) | 3.61±1.072 (78) | ||
| Week 21 | −0.04±0.741 (63) | −0.11±0.757 (60) | −0.22 (−0.47 to 0.03) | 0.083 |
| Week 34 | −0.16±0.883 (47) | −0.31±0.708 (49) | −0.22 (−0.54 to 0.10) | 0.174 |
| HDL-C (mmol/l) | ||||
| Baseline | 1.18±0.295 (81) | 1.17±0.301 (78) | ||
| Week 21 | −0.02±0.196 (64) | 0.04±0.170 (60) | 0.05 (−0.01 to 0.12) | 0.106 |
| Week 34 | 0.00±0.134 (47) | 0.03±0.161 (49) | 0.03 (−0.03 to 0.09) | 0.340 |
| Triglycerides (mmol/l)a | ||||
| Baseline | 2.11±1.487 (81) | 1.81±1.58 (78) | ||
| Week 21 | 0.53±2.545 (64) | −0.03±0.484 (60) | −0.13 (−0.27 to 0.00) | 0.047 |
| Week 34 | 0.33±1.279 (47) | −0.07±0.638 (49) | −0.2 (−0.35 to −0.05) | 0.009 |
| NEFA, fasting (mmol/l)a | ||||
| Baseline | 328.9±142.40 (79) | 389.4±207.36 (76) | ||
| Week 21 | 47.9±181.68 (62) | −21.9±178.29 (56) | −0.04 (−0.23 to 0.15) | 0.686 |
| Week 34 | 3.2±174.00 (47) | −22.6±174.71 (49) | −0.03 (−0.26 to 0.2) | 0.792 |
| NEFA, 30-min (mmol/l)a | ||||
| Baseline | 209.9±134.26 (79) | 218.7±182.35 (76) | ||
| Week 21 | 14.1±157.61 (62) | −6.7±116.83 (56) | −0.25 (−0.46 to −0.03) | 0.028 |
| Week 34 | 14.3±180.17 (46) | 10.6±119.77 (49) | −0.09 (−0.32 to 0.14) | 0.428 |
| aNEFA, 2-hour | ||||
| Baseline | 100.6±138.19 (78) | 90.1±116.17 (75) | ||
| Week 21 | 19.3±143.4 (62) | 4.0±107.04 (55) | −0.32 (−0.63 to −0.02) | 0.038 |
| Week 34 | −16.7±159.28 (46) | −4.6±80.85 (48) | −0.14 (−0.42 to 0.14) | 0.313 |
↵a Endpoints for triglycerides and NEFA were log-transformed before analysis and the adjusted treatment differences are presented on a logscale. HDL-C = high-density-lipoprotein cholesterol. LDL-C = low-density-lipoprotein cholesterol. NEFA = non-esterified fatty acid.